Pfizer receives European approval for Oncology Biosimilar, RUXIENCE (rituximab) Medical Dialogues Bureau5 April 2020 2:15 PM ISTNew York: Pfizer Inc. has announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar...
CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug Farhat Nasim27 Oct 2019 11:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO), recently recommended drugmaker,...
Pfizer gets USFDA nod for biosimilar to Rituximab Medical Dialogues Bureau25 July 2019 8:59 AM ISTRuxience is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. Ruxience is...